Project Grant R03CA303759
Award Date
7/10/25
Completion Date
6/30/27
Dollars Obligated
$161K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $220,340 Project Grant (CFDA 93.398 - Cancer Research Manpower) to Baylor College of Medicine, effective July 31, 2024 through March 31, 2025. The grant supports a research project titled "Targeting the RNA Helicase DDX6 in Acute Myeloid Leukemia". The project aims to conduct innovative research on acute myeloid leukemia (AML), an aggressive blood cancer, with a focus on understanding the role of the RNA helicase DDX6 and developing new...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $542,663 to The University of Texas M.D. Anderson Cancer Center to conduct preclinical research on novel therapies for acute myeloid leukemia (AML). The research aims to evaluate the efficacy of BRG1/BRM antagonists, such as the inhibitor FHD-286 and the degrader AU15330, in overcoming resistance to menin inhibitors in AML with MLL rearrangement or mutant NPM1. The studies...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at Case Western Reserve University to investigate a novel combination therapy approach for acute myeloid leukemia (AML). The $491,357 award, granted on March 15, 2025, aims to establish the mechanistic role of mTOR hyperactivation as a chemosensitizer for AML. Key objectives include mapping mitochondrial respiratory defects, identifying AML cell susceptibility to metabolic...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), is providing $344,111 to Loyola University of Chicago to conduct research on targeting panoptotic pathways for the treatment of myelodysplastic syndromes (MDS). The primary objectives are to investigate whether inhibition of RIPK1 and TBK1 can prevent MDS and eliminate mutant hematopoietic stem/progenitor cells, thereby restoring blood cell counts and preventing...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $222,432 to St. Jude Children's Research Hospital Inc. to investigate the role of the protein Caspase-8 in cancer, anti-cancer immunity, and CAR-T cell function. The project aims to understand how Caspase-8 in cancer cells and the tumor microenvironment influences anti-cancer immunity and CAR-T cell efficacy. It will involve comparing relevant murine cancer cell lines with and without...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to understand the fundamental biological mechanisms underlying acute myeloid leukemia (AML). The $483,760 award, effective April 1, 2025 through March 31, 2030, will enable The Trustees of the University of Pennsylvania to investigate the role of the DCAF15 E3 ligase in regulating the cohesin complex and genome architecture in AML. Key objectives include deciphering the...
This federal Project Grant award of $147,486, awarded on December 1, 2025 by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports research by Baylor College of Medicine to develop a novel "RECON" immune tolerization strategy. The goal is to investigate the trade-offs between oncogene pathogenicity and immunogenicity, which could enable dissection of the genetic and phenotypic alterations governing immune evasion independently of tumorigenesis during...
This Project Grant award of $662,938, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research at Northwestern University to investigate the role of gain-of-function mutant p53 proteins in acute myeloid leukemia (AML). The central objective is to determine how these p53 mutations promote leukemia-initiating cell self-renewal, chromatin accessibility, and 3D chromatin structure, which may contribute to therapy resistance in AML....
This $194,688 Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) supports research by Indiana University Indianapolis to investigate the role of the GATA2 gene in acute myeloid leukemia (AML) and the MonoMAC syndrome. The key objectives are to: 1) Define the genes regulated by the normal GATA2 protein and how their expression is altered by AML- and MonoMAC-associated GATA2 mutations, using a novel mouse model and overexpression studies in...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $415,259 to the Rector & Visitors of the University of Virginia to conduct research on the role of long noncoding RNAs in acute myeloid leukemia (AML). The project aims to 1) determine the role of a specific regulatory RNA in primary and relapsed AML, and 2) define the mechanism underlying its deregulation in AML. This research will provide insights into how noncoding RNAs...